Perrigo (NYSE:PRGO) Sets New 52-Week Low – Should You Sell?

Perrigo Company plc (NYSE:PRGO)’s stock price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $9.23 and last traded at $9.2450, with a volume of 5586251 shares traded. The stock had previously closed at $9.65.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Argus upgraded shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. Finally, Canaccord Genuity Group dropped their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Trading Down 4.2%

The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -0.90, a price-to-earnings-growth ratio of 1.19 and a beta of 0.41. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The firm’s 50 day moving average is $13.40 and its 200 day moving average is $16.21.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. Perrigo’s quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be given a $0.29 dividend. The ex-dividend date is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 12.5%. Perrigo’s dividend payout ratio (DPR) is -11.28%.

Institutional Trading of Perrigo

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC purchased a new stake in Perrigo during the fourth quarter valued at about $283,000. Alpine Global Management LLC purchased a new position in shares of Perrigo in the fourth quarter worth approximately $181,000. Aristides Capital LLC acquired a new stake in shares of Perrigo during the fourth quarter valued at approximately $212,000. T. Rowe Price Investment Management Inc. lifted its position in shares of Perrigo by 35.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,386,111 shares of the company’s stock valued at $19,295,000 after acquiring an additional 363,501 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Perrigo by 134.2% in the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock worth $63,230,000 after purchasing an additional 2,602,724 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.